Acelyrin Inc is a biopharmaceutical company focused on developing innovative therapies for patients with chronic and debilitating conditions
The company specializes in advancing treatments that target unmet medical needs, with particular emphasis on autoimmune and inflammatory diseases. Through its robust pipeline, Acelyrin aims to improve the quality of life for patients by harnessing cutting-edge science and technology to create effective and safe therapeutic options. The organization is committed to rigorous clinical research and collaboration with healthcare professionals to bring new solutions to the market.
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
ACELYRIN shares are moving higher on Friday after the company announced that it will reveal Phase 2 data and announce Phase 3 plans for Subcutaneous Lonigutamab at a virtual investor event.
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half of 2024.
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show sustained clinical improvements, with HiSCR75 and HiSCR100 achievements. Phase 3 trial results expected by end of 2024.
